Abstract
The last decade has witnessed the publication of a large number of clinical trials primarily using bone marrow-derived stem cells as the injected cell. These "first-generation" clinical trials have advanced our understanding and shown us that (1) cell therapy is safe, (2) cell therapy has been modestly effective, and (3) in humans, bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels (or at least in sufficient numbers to have any effect). The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The new direction for clinical trials includes the use of stem cells capable of cardiac lineage, such as endogenous cardiac stem cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 187-194 |
| Number of pages | 8 |
| Journal | Methodist DeBakey cardiovascular journal |
| Volume | 9 |
| Issue number | 4 |
| State | Published - 2013 |
Fingerprint
Keywords
- heart failure
- regenerative medicine
- stem cell therapy
ASJC Scopus subject areas
- Medicine(all)
Cite this
Stem cell therapy for heart failure. / Michler, Robert E.
In: Methodist DeBakey cardiovascular journal, Vol. 9, No. 4, 2013, p. 187-194.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Stem cell therapy for heart failure
AU - Michler, Robert E.
PY - 2013
Y1 - 2013
N2 - The last decade has witnessed the publication of a large number of clinical trials primarily using bone marrow-derived stem cells as the injected cell. These "first-generation" clinical trials have advanced our understanding and shown us that (1) cell therapy is safe, (2) cell therapy has been modestly effective, and (3) in humans, bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels (or at least in sufficient numbers to have any effect). The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The new direction for clinical trials includes the use of stem cells capable of cardiac lineage, such as endogenous cardiac stem cells.
AB - The last decade has witnessed the publication of a large number of clinical trials primarily using bone marrow-derived stem cells as the injected cell. These "first-generation" clinical trials have advanced our understanding and shown us that (1) cell therapy is safe, (2) cell therapy has been modestly effective, and (3) in humans, bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels (or at least in sufficient numbers to have any effect). The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The new direction for clinical trials includes the use of stem cells capable of cardiac lineage, such as endogenous cardiac stem cells.
KW - heart failure
KW - regenerative medicine
KW - stem cell therapy
UR - http://www.scopus.com/inward/record.url?scp=84918528597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84918528597&partnerID=8YFLogxK
M3 - Article
C2 - 24298308
AN - SCOPUS:84918528597
VL - 9
SP - 187
EP - 194
JO - Methodist DeBakey cardiovascular journal
JF - Methodist DeBakey cardiovascular journal
SN - 1947-6094
IS - 4
ER -